Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 18/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26986875 | 0.89 | CTSC (0.53) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL27124677 | 0.89 | CTSC (0.53) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL31670685 | 0.84 | CTSC (0.52) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL27136158 | 0.81 | CTSC (0.55) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL26986843 | 0.81 | CTSC (0.55) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL30738872 | 0.78 | CTSC (0.56) | CTSCKCNH2CTSK | |
| SCHEMBL30195065 | 0.75 | CTSC (0.56) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL20162060 | 0.75 | CTSC (0.56) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL26986850 | 0.74 | CTSC (0.58) | CTSCKCNH2LTB4RLTB4R2CTSK | |
| SCHEMBL27131713 | 0.74 | CTSC (0.58) | CTSCKCNH2LTB4RLTB4R2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP9, DPP4, DPP3 | CTSC 7/4885KCNH2 2233/4885LTB4R 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.